Ugur Sahin plans $93.9M BioNTech (BNTX) ADS sale under Form 144

Rhea-AI Filing Summary

BioNTech SE insider Ugur Sahin has filed a Form 144 indicating an intent to sell 858,209 American Depositary Shares (ADS), representing ordinary shares with no par value. The planned sale through Berenberg Capital Markets LLC on the Nasdaq Global Select Market has an aggregate market value of $93,870,900.42, while 240,455,450 ADS were outstanding.

The securities to be sold were acquired via stock option exercises on 11/21/2022 (856,186 ordinary shares) and 08/09/2024 (2,023 ordinary shares). Over the past three months, Sahin has already sold multiple ADS blocks, including 72,970 ADS for $7,901,797.25 on 01/14/2026 and 62,000 ADS for $7,451,792.40 on 01/22/2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	Berenberg Capital Markets LLC 1251 Avenue of the Americas 53rd Floor New York NY 10020	858209	93870900.42	240455450	02/12/2026	Nasdaq Global Select

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares, no par value per share	11/21/2022	Stock Option Exercise	BioNTech SE			856186	11/21/2022	Stock Option Exercise
Ordinary Shares, no par value per share	08/09/2024	Stock Option Exercise	BioNTech SE			2023	08/09/2024	Stock Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/27/2026	42000	5004585.60
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/26/2026	3000	354000.00
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/23/2026	2500	295711.50
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/22/2026	62000	7451792.40
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/21/2026	24538	2737038.98
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/16/2026	23000	2507395.60
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/15/2026	1913	206044.64
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/14/2026	72970	7901797.25
Ugur Sahin An der Goldgrube 12 Mainz 2M 55131	American Depositary Shares representing ordinary shares, no par value per share	01/13/2026	24000	2573198.40

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BioNTech (BNTX) Form 144 filing disclose?

The filing shows Ugur Sahin’s intent to sell 858,209 American Depositary Shares of BioNTech SE. These ADS are planned to be sold on the Nasdaq Global Select Market through Berenberg Capital Markets LLC, with an indicated aggregate market value of approximately $93.9 million.

How many BioNTech (BNTX) shares are planned to be sold under this Form 144?

The notice covers a proposed sale of 858,209 American Depositary Shares. This figure represents the maximum number of ADS Sahin intends to sell in this transaction, as disclosed in the securities information section of the Form 144 filing for BioNTech SE.

What is the approximate value of the BioNTech (BNTX) shares to be sold?

The planned sale of 858,209 American Depositary Shares has an aggregate market value of $93,870,900.42. This valuation is based on market prices at the time of preparing the Form 144, providing investors a sense of the potential transaction’s dollar size.

When is the planned sale date for the BioNTech (BNTX) shares in this Form 144?

The approximate sale date disclosed is February 12, 2026. This date reflects when the seller expects to begin executing transactions for the 858,209 American Depositary Shares on the Nasdaq Global Select Market, subject to market conditions and applicable regulations.

How were the BioNTech (BNTX) shares in this Form 144 originally acquired?

The shares were acquired through stock option exercises from BioNTech SE. One block of 856,186 ordinary shares was acquired on November 21, 2022, and another 2,023 ordinary shares on August 9, 2024, with payment also made via stock option exercises on those dates.

What recent BioNTech (BNTX) share sales by Ugur Sahin are disclosed?

The filing lists several ADS sales in January 2026. Examples include 72,970 ADS sold on January 14, 2026 for $7,901,797.25, and 62,000 ADS sold on January 22, 2026 for $7,451,792.40, showing recent sizable transactions before the new planned sale.

Which broker and exchange are involved in the BioNTech (BNTX) Form 144 sale?

Berenberg Capital Markets LLC is the designated broker for the planned sale. The 858,209 American Depositary Shares are expected to be sold on the Nasdaq Global Select Market, as specified in the securities information section of the Form 144 filing for BioNTech SE.